CN1176113A - Compound bufonin of bufo gargarizans - Google Patents
Compound bufonin of bufo gargarizans Download PDFInfo
- Publication number
- CN1176113A CN1176113A CN96115972A CN96115972A CN1176113A CN 1176113 A CN1176113 A CN 1176113A CN 96115972 A CN96115972 A CN 96115972A CN 96115972 A CN96115972 A CN 96115972A CN 1176113 A CN1176113 A CN 1176113A
- Authority
- CN
- China
- Prior art keywords
- radix
- bufonin
- compound
- prescription
- cutis bufonis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Compound bufonin is Chinese medicine oral or capsule prepared with toad skin, giant knotweed rhizomed, red sage root and other Chinese medicinal materials. It has functions of detoxication, strengthening body resistance and eliminating evil, dispersing blood clots and resolving hard lumps, and is used to cure hepatitis B, AIDS and cancer. It has high cure effect, but low cost.
Description
The invention belongs to the Chinese medicine technical field, relate to a kind of medicine for the treatment of hepatitis B and AIDS.
A few days ago, hepatitis B virus, HIV (human immunodeficiency virus) infection still there is not specific short.Clinically used drug price costlinesses such as for many years interferon, acycloguanosine, suramin, side effect is big, interferon is gone into weak curative effect to east.In recent years discover that Venenum Bufonis has the AIDS resisting toxic action, the cinobufacin that extracts from Cutis Bufonis (Cinobufotalin) has tangible anti-HBV effect, but cinobufacin need be through intravenous administration, and there is zest the part, also can cause the heart condition reaction occasionally.
Task of the present invention provides and a kind ofly treats hepatitis B, AIDS good effect, has no side effect, cost is low, the compound bufonin of bufo gargarizans preparation of taking convenience, thereby overcomes the deficiency of existing medicine effectively.
Task of the present invention realizes with following scheme.
Its basic prescription is (unit: kg is down together):
Cutis Bufonis 0.1-1.0, Rhizoma Polygoni Cuspidati 1.0-3.0, Herba Hedyotidis Diffusae 1.0-3.0, Radix Astragali 1.0-3.0, Radix Salviae Miltiorrhizae 1.0-3.0, Radix Glycyrrhizae 0.5-1.5.
Its best prescription is:
Cutis Bufonis 0.4-0.6, Rhizoma Polygoni Cuspidati 1.8-2.2, Herba Hedyotidis Diffusae 1.0-3.0, Radix Astragali 1.8-2.2, Radix Salviae Miltiorrhizae 1.8-2.2, Radix Glycyrrhizae 0.8-1.0.
In order to strengthen the antiviral efficacy of this medicine, can also assist in the prescription of the present invention and be furnished with:
Flos Lonicerae 0.5-2.0, Folium Crataegi 1.0-3.0.
In order to enlarge the curative effect scope of medicine of the present invention,, also can assist among the we and be furnished with as anticancer, anti-liver cirrhosis effect:
Radix Bupleuri 0.5-1.0, Radix Curcumae 1.0-2.0, Radix Codonopsis 1.0-2.0, Radix Angelicae Sinensis 1.0-2.0, Radix Paeoniae Rubra 1.0-2.0, Rhizoma Atractylodis Macrocephalae 1.0-3.0, Fructus Jujubae 0.5-1.0.
Medicine of the present invention can be prepared into oral liquid, also can be prepared into capsule.Preparation technology is when being prepared into oral liquid:
1. after dry Cutis Bufonis being soaked about 12 hours with clear water, clean;
2. Cutis Bufonis other medical material in prescription that will handle through step 1 use the decocting method decocting, get decocting liquid concentrated put cold;
3. put cold concentrated solution through step 2 and add ethanol stirring, precipitation, filter, be evaporated to the extractum shape;
The extractum that makes through step 3 add that proper honey, second moor that golden ethyl ester, essence, distilled water stir evenly, Cryoprecipitation filtration, packing, sterilization, be compound bufonin of bufo gargarizans oral liquor medicine of the present invention.
When being prepared into capsule formulation, preparation technology is:
1. Cutis Bufonis is dipped to softly, boiled 5-10 minute, coarse powder is worn in oven dry, respectively soaks 24 hours with ethyl acetate and chloroform successively, soaked 2 hours with clear water, oven dry grinds to form fine powder, or after the Cutis Bufonis maceration cleaned, use the decocting method decocting, get decocting liquid and be condensed into extractum, it is standby to grind to form fine powder after the drying;
2. with other medical material in prescription decocting together, be condensed into extractum, dry, be ground into powder;
The Cutis Bufonis powder of the extract powder of other medical materials that step 2 is made and step 1 gained or Cutis Bufonis extract powder mixing, add dextrin and granulate, adorn capsule in right amount, be compound bufonin of bufo gargarizans capsule of the present invention.
Medicine of the present invention is compared good effect with existing medicine, and the medicine source is wide, and preparation technology is simple, and cost is low, and taking convenience has no side effect.Confirm that through Beijing Medical University's experiment in vitro oral liquid of the present invention when concentration is 0.2mg/ml, reaches 98.2% and 100% to HBsAg and HBeAg suppression ratio, therapeutic index reaches 32 (therapeutic index>2 are for effective), no cytotoxicity.The capsule clinical practice also has good efficacy, is a kind of comparatively ideal medicine of treatment hepatitis B and AIDS.
Embodiment one
Prescription: Cutis Bufonis 0.5kg Rhizoma Polygoni Cuspidati 2kg Herba Hedyotidis Diffusae 2kg Radix Salviae Miltiorrhizae 1.5kg Radix Astragali 1.5kg Radix Codonopsis 1.5KG Radix Glycyrrhizae 1kg, Mel, sorbic acid, essence are an amount of.
Method for making: dry Cutis Bufonis was soaked about 12 hours, clean, add Six-element medical herbs such as Rhizoma Polygoni Cuspidati and decoct 3 times, each 1 hour, filter, merging filtrate is concentrated into 5000ml, put coldly, 95% ethanol that adds doubling dose stirs evenly, and places 24 hours, filter, adding Mel, second are moored golden ethyl ester, essence, distilled water to 5000ml (every ml contains crude drug 2g).Cold preservation, filter, every 10ml be distributed into 500, with 100 degree sterilizations sealed in 30 minutes, per 6 one box-packed casees.
Character: this product is a brown liquid, and flavor is bitter, little sweet slightly.
Check: this product relative density should be 1.10-1.25, and pH value should be 4.0-6.0.Embodiment two
Prescription: Cutis Bufonis 0.5Kg, Rhizoma Polygoni Cuspidati 2.0kg, Herba Hedyotidis Diffusae 2.5kg, Flos Lonicerae 2.0kg, Radix Astragali 2.5kg, Radix Salviae Miltiorrhizae 2.0kg, Folium Crataegi 2.5kg, Radix Glycyrrhizae 1.0kg.
Method for making: soak Cutis Bufonis 8-12 hour (1), boiled 5-10 minute, and coarse powder is dry grinded in baking (roasting), respectively soaked 24 hours with ethyl acetate and chloroform, and with clear water immersion 2 hours, to wear into fine powder standby for drying again; (2) 7 flavor medicines such as Rhizoma Polygoni Cuspidati are decocted 3 times, each 1 hour, filter, merging filtrate is condensed into extractum, and it is standby that 80 mesh sieves were pulverized in oven dry, and (4) add the extract powder of 7 flavor medicines with the Cutis Bufonis powder, and adding dextrin again, to make granule in right amount encapsulated, every 0.3 gram.Embodiment three
Prescription: Cutis Bufonis 0.5Kg, Rhizoma Polygoni Cuspidati 2.0kg, Herba Hedyotidis Diffusae 2.0kg, Flos Lonicerae 2.0kg, Radix Astragali 2.0kg, Radix Codonopsis 1.5kg, Radix Bupleuri 1.0kg, Radix Salviae Miltiorrhizae 2.0kg, Radix Curcumae 1.5kg, Folium Crataegi 2.0kg, Radix Angelicae Sinensis 1.5Kg, Radix Paeoniae Rubra 1.5kg, Rhizoma Atractylodis Macrocephalae 2.0kg, Fructus Jujubae 0.5kg, Radix Glycyrrhizae 1.0kg.
Method for making: soak Cutis Bufonis 12 hours (1), and clean the back and decoct 3 times, each 1 hour, filter, merging filtrate is condensed into extractum, and it is standby that drying is worn into fine powder; (2) 14 flavor medicines such as Rhizoma Polygoni Cuspidati are decocted 3 times, each 1 hour, filter, merging filtrate is condensed into extractum, and it is standby that 80 mesh sieves were pulverized in oven dry, and (3) add the extract powder of 7 flavor medicines with the Cutis Bufonis extract powder, and adding dextrin again, to make granule in right amount encapsulated, every 0.3 gram.
Case one, Wang, the man, 31 years old, because of weak, xerostomia 1 month is gone to a doctor, and has a blood test and finds that HBsAg.HBeAg.-HBC is all positive, the every index of liver function is all normal, examines to hepatitis B virus and carry, promptly give compound bufonin of bufo gargarizans oral liquid 10ML oral, every day 3 times, checked hepatitis b virus marker after taking medicine 30 days, wherein HBeAg turns out cloudy, and anti--HBe sun changes, liver function is normal, follows up a case by regular visits to still normal after 3 months.
Case two, the time, the woman, 39 years old, suffer from 3 years obstinates of chronic viral hepatitis B and go to a doctor, have a blood test and find SGPT210 unit, total protein 54g/L, A/G falls to be worth, the HBsAg.HBV-DNA positive gives 2 of compound bufonin of bufo gargarizans capsules, and every day 3 times is oral, be aided with that treatments such as silybin, protein-zinc check in 6 months liver function is normal, HBV-DNA turns out cloudy, follows up a case by regular visits to not recurrence in 6 months.
Case three, Liu, the man, 16 years old, the discovery HBsAg.HBeAg.HBV-DNA positive of having a medical check-up, the intramuscular injection polyporusum bellatus. Hepatitis B virus vaccine do not take effect in 3 months, use the compound bufonin of bufo gargarizans capsule instead and liver-benefiting is oral, intramuscular injection thymosin 2 times weekly, after the medication three months, it is normal to look into liver function, and HBeAg.HBV-DNA turns out cloudy, and follows up a case by regular visits to one every year normally.
Claims (7)
1. compound bufonin of bufo gargarizans medicine.The basic prescription that it is characterized in that it is:
Cutis Bufonis 0.1-1.0, Rhizoma Polygoni Cuspidati 1.0-3.0, Herba Hedyotidis Diffusae 1.0-3.0, Radix Astragali 1.0-3.0, Radix Salviae Miltiorrhizae 1.0-3.0, Radix Glycyrrhizae 0.5-1.5.
2. compound bufonin of bufo gargarizans medicine according to claim 1 is characterized in that said prescription the best is: Cutis Bufonis 0.4-0.6, Rhizoma Polygoni Cuspidati 1.8-2.2, Herba Hedyotidis Diffusae 1.0-3.0, Radix Astragali 1.8-2.2, Radix Salviae Miltiorrhizae 1.8-2.2, Radix Glycyrrhizae 0.8-1.0.
3. according to claims 1 or 2 described compound bufonin of bufo gargarizans medicines, it is characterized in that assisting in the said prescription and be furnished with: box Flos Lonicerae 0.5-2.0, Folium Crataegi 1.0-3.0.
4. according to claims 1.2 described compound bufonin of bufo gargarizans medicines, it is characterized in that also assisting in the said prescription and be furnished with: Radix Bupleuri 0.5-1.0, Radix Curcumae 1.0-2.0, Radix Codonopsis 1.0-2.0, Radix Angelicae Sinensis 1.0-2.0, Radix Paeoniae Rubra 1.0-2.0, Rhizoma Atractylodis Macrocephalae 1.0-3.0, Fructus Jujubae 0.5-1.0.
5. according to claims 3 described compound bufonin of bufo gargarizans medicines, it is characterized in that also assisting in the said prescription and be furnished with: Radix Bupleuri 0.5-1.0, Radix Curcumae 1.0-2.0, Radix Codonopsis 1.0-2.0, Radix Angelicae Sinensis 1.0-2.0, Radix Paeoniae Rubra 1.0-2.0, Rhizoma Atractylodis Macrocephalae 1.0-3.0, Fructus Jujubae 0.5-1.0.
6. according to claims 1 described compound bufonin of bufo gargarizans medicine, it is characterized in that pharmaceutical formulation is an oral liquid, its preparation technology is:
(1) dry Cutis Bufonis is soaked about 12 hours with clear water after, clean;
(2) Cutis Bufonis other medical material in prescription that will handle through step 1 use the decocting method decocting, get decocting liquid concentrated put cold;
(3) put cold concentrated solution through step 2 and add ethanol stirring, precipitation, filter, be evaporated to the extractum shape;
(4) extractum that makes through step 3 adds proper honey, second and moors golden ethyl ester, essence, distilled water and stir evenly, and Cryoprecipitation filters, and packing, sterilization are the compound bufonin of bufo gargarizans oral liquid.
7. compound bufonin of bufo gargarizans medicine according to claim 1 is characterized in that pharmaceutical formulation is a capsule, and preparation technology is:
(1) Cutis Bufonis is dipped to soft, boiled 5-10 minute, coarse powder is worn in oven dry, respectively soaks 24 hours with ethyl acetate and chloroform successively, soaks 2 hours with clear water, and it is standby that oven dry grinds to form fine powder; Or after the Cutis Bufonis maceration cleaned, use the decocting method decocting, and get decocting liquid and be condensed into extractum, grind to form fine powder after the drying;
(2), be condensed into extractum, dry, be ground into powder with other medical material in prescription decocting together;
(3) the Cutis Bufonis powder of the extract powder of other medical materials that step 2 is made and step 1 gained or Cutis Bufonis extract powder mixing, add dextrin and granulate, adorn capsule in right amount, be the compound bufonin of bufo gargarizans capsule.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN96115972A CN1059556C (en) | 1996-09-09 | 1996-09-09 | Compound bufonin of bufo gargarizans |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN96115972A CN1059556C (en) | 1996-09-09 | 1996-09-09 | Compound bufonin of bufo gargarizans |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1176113A true CN1176113A (en) | 1998-03-18 |
CN1059556C CN1059556C (en) | 2000-12-20 |
Family
ID=5123171
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN96115972A Expired - Fee Related CN1059556C (en) | 1996-09-09 | 1996-09-09 | Compound bufonin of bufo gargarizans |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1059556C (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101020027B (en) * | 2006-12-01 | 2010-05-26 | 广州中医药大学热带医学研究所 | Medicine composition for preventing and treating AIDS and its preparation process and use |
EP2353602A3 (en) * | 2009-08-07 | 2011-11-23 | Zheming Jin | Natural pharmaceutical preparations for increasing albumin |
CN101214285B (en) * | 2008-01-07 | 2012-02-01 | 中国人民解放军第二军医大学 | Use of giant knotweed rhizome extract in preparing product for resisting AIDS virus and hepatitis B |
CN102397430A (en) * | 2010-09-10 | 2012-04-04 | 徐向田 | Cinobufotalin liver nourishing capsules |
CN103239674A (en) * | 2013-04-17 | 2013-08-14 | 上海铂康生物科技有限公司 | Antineoplastic traditional Chinese medicine composition and preparation method thereof |
CN107496672A (en) * | 2017-08-24 | 2017-12-22 | 四川省众生缘农业科技开发有限公司 | A kind of Chinese patent drug for clearing liver and improving vision, controlling liver liver protection |
CN113332385A (en) * | 2021-06-09 | 2021-09-03 | 上海天蟾生物科技有限公司 | Preparation method of arenobufagin hard-hardness-softening liver-softening tablet |
CN113476536A (en) * | 2021-06-16 | 2021-10-08 | 湖北大学 | Traditional Chinese medicine micro-ecological preparation and application thereof in preparation of anti-hepatitis B virus medicines |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1077389A (en) * | 1993-02-26 | 1993-10-20 | 王平 | " gan shi xin " oral liquid |
-
1996
- 1996-09-09 CN CN96115972A patent/CN1059556C/en not_active Expired - Fee Related
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101020027B (en) * | 2006-12-01 | 2010-05-26 | 广州中医药大学热带医学研究所 | Medicine composition for preventing and treating AIDS and its preparation process and use |
CN101214285B (en) * | 2008-01-07 | 2012-02-01 | 中国人民解放军第二军医大学 | Use of giant knotweed rhizome extract in preparing product for resisting AIDS virus and hepatitis B |
EP2353602A3 (en) * | 2009-08-07 | 2011-11-23 | Zheming Jin | Natural pharmaceutical preparations for increasing albumin |
CN102397430A (en) * | 2010-09-10 | 2012-04-04 | 徐向田 | Cinobufotalin liver nourishing capsules |
CN102397430B (en) * | 2010-09-10 | 2014-11-19 | 徐向田 | Cinobufotalin liver nourishing capsules |
CN103239674A (en) * | 2013-04-17 | 2013-08-14 | 上海铂康生物科技有限公司 | Antineoplastic traditional Chinese medicine composition and preparation method thereof |
CN103239674B (en) * | 2013-04-17 | 2015-04-22 | 上海铂康生物科技有限公司 | Antineoplastic traditional Chinese medicine composition and preparation method thereof |
CN107496672A (en) * | 2017-08-24 | 2017-12-22 | 四川省众生缘农业科技开发有限公司 | A kind of Chinese patent drug for clearing liver and improving vision, controlling liver liver protection |
CN113332385A (en) * | 2021-06-09 | 2021-09-03 | 上海天蟾生物科技有限公司 | Preparation method of arenobufagin hard-hardness-softening liver-softening tablet |
CN113476536A (en) * | 2021-06-16 | 2021-10-08 | 湖北大学 | Traditional Chinese medicine micro-ecological preparation and application thereof in preparation of anti-hepatitis B virus medicines |
CN113476536B (en) * | 2021-06-16 | 2022-04-01 | 湖北大学 | Traditional Chinese medicine micro-ecological preparation and application thereof in preparation of anti-hepatitis B virus medicines |
Also Published As
Publication number | Publication date |
---|---|
CN1059556C (en) | 2000-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1044974C (en) | Anti- hepatitis B preparation | |
ZA200302647B (en) | Novel medicinal herbal composition for treating liver diseases. | |
CN1067267C (en) | Medicine for treating hepatitis B | |
CN1176113A (en) | Compound bufonin of bufo gargarizans | |
CN1145240A (en) | Medicinal compsn. for prevention of Aids virus and cancer | |
CN1056755C (en) | Medicine of curing hepatitis | |
CN1228063C (en) | Medicine for treating liver disease | |
CN1098089C (en) | Medicine for treating hepatitis and liver fibrosis, and method for preparing same | |
CN1969940A (en) | Antivirus pharmaceutical composition | |
CN1160560A (en) | Chinese patent drug for curing leukopenia and its preparation process | |
CN1180821C (en) | Medicine for treating cerebral thrombus and its prepn | |
CN1098294A (en) | Manganning medicine | |
CN1453014A (en) | Chinese medicine prepn for preventing fibrillated liver and treating hepatocirrhosis | |
CN101199667A (en) | Chinese medicine for treating leukemia, aplastic anemia | |
CN1340353A (en) | Orally-applied medicine for treating hepatism and its preparing process | |
CN1086129C (en) | Hepatitis restoration pill | |
CN1171257A (en) | Chinese-herbal medicine for curing hepatitis B and its preparing process | |
CN1030245C (en) | "Gantaibao" capsule (a kind of medicine for liver) and preparation process threof | |
CN1142391A (en) | Oral liquid | |
CN101700323B (en) | Pharmaceutical composition for preventing and treating liver cancer | |
CN105641168A (en) | Medicine for treating viral hepatitis B and viral hepatitis C and preparation method of medicine | |
CN1814250A (en) | Chinese medicine composition for treating liver cirrhosis ascites and use thereof | |
CN1291729C (en) | Antiviral Chinese medicine prepn of Hypericum perforatumand its prepn process | |
CN1108943A (en) | Medicine "Yigankang" for hepatitis B and its preparation | |
CN1118263A (en) | Life star-Chinese medicine for cancers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |